MTOR and cancer: While, generally, tRNA anticodon pools were found to be stable across human tissues [13, 29], alterations in tRNA expression were observed across cancer types, mediated via activation of oncogenic pathways such as PI3K/AKT/mTOR, and MYC, which regulate RNA polymerase III-mediated tRNA expression [8, 28].